Intestinal barrier perform requires intricate cooperation between intestinal epithelial cells and immune cells. Enteropathogens are in a position to invade the intestinal lymphoid tissue often known as Peyer’s patches (PPs) and disrupt the integrity of the intestinal barrier. However, the underlying molecular mechanisms of this course of are poorly understood.
In mice contaminated with Yersinia pseudotuberculosis, we discovered that PP barrier dysfunction depends on the Yersinia virulence plasmid and the expression of TLR-2 by hematopoietic cells, however not by intestinal epithelial cells. Upon TLR-2 stimulation, Y. pseudotuberculosis-infected monocytes activated caspase-1 and produced IL-1β. In flip, IL-1β elevated NF-κB and myosin gentle chain kinase activation in intestinal epithelial cells, thus disrupting the intestinal barrier by opening the tight junctions. Therefore, Y. pseudotuberculosis subverts intestinal barrier perform by altering the interaction between immune and epithelial cells throughout an infection.
CBLB613: a <em>TLR</em> <em>2</em>/6 agonist, pure lipopeptide of Mycoplasma arginini , as a novel radiation countermeasure.
To date, there aren’t any secure and efficient medicine obtainable for defense towards ionizing radiation injury. Therefore, a terrific want exists to establish and develop non-toxic brokers that can be helpful as radioprotectors or postirradiation therapies below a wide range of operational eventualities. We have developed a brand new pharmacological agent, CBLB613 (a naturally occurring Mycoplasma-derived lipopeptide ligand for Toll-like receptor 2/6), as a novel radiation countermeasure.
Using CD2F1 mice, we investigated CBLB613 for toxicity, immunogenicity, radioprotection, radiomitigation and pharmacokinetics. We additionally evaluated CBLB613 for its results on cytokine induction and radiation-induced cytopenia in unirradiated and irradiated mice. The no-observable-adverse-effect degree of CBLB613 was 1.79 mg/kg and 1 mg/kg for single and repeated doses, respectively.
CBLB613 considerably protected mice towards a deadly dose of (60)Co γ radiation. The dose discount issue of CBLB613 as a radioprotector was 1.25. CBLB613 additionally mitigated the consequences of (60)Co γ radiation on survival in mice. In each irradiated and unirradiated mice, the drug stimulated induction of interleukin-1β (IL-1β), IL-6, IL-10, IL-12, keratinocyte-derived chemokine, granulocyte colony-stimulating issue, granulocyte-macrophage colony-stimulating issue, and tumor necrosis factor-1α.
CBLB613 additionally lowered radiation-induced cytopenia and elevated bone marrow cellularity in irradiated mice. Our immunogenicity research demonstrated that CBLB613 isn’t immunogenic in mice, indicating that it may very well be developed as a radioprotector and radiomitigator for people towards the possibly deadly results of radiation publicity.
Role of Toll-like receptor (<em>TLR</em>) <em>2</em> in experimental Bacillus cereus endophthalmitis.
Bacillus cereus causes a uniquely fast and blinding intraocular an infection, endophthalmitis. B. cereus replicates within the eye, synthesizes quite a few toxins, and incites explosive intraocular irritation. The mechanisms concerned within the fast and explosive intraocular immune response haven’t been addressed. Because Toll-like receptors (TLRs) are integral to the preliminary recognition of organisms throughout an infection, we hypothesized that the uniquely explosive immune response noticed throughout B. cereus endophthalmitis is immediately influenced by the presence of TLR2, a identified gram-positive pathogen recognition receptor.
To deal with this speculation, we in contrast the programs of experimental B. cereus endophthalmitis in wild kind C57BL/6J mice to that of age-matched homozygous TLR2(-/-) mice. Output parameters included evaluation of bacterial progress, inflammatory cell (PMN) infiltration, cytokine/chemokine kinetics, retinal perform testing, and histology, with N≥Four eyes/assay/time level/mouse pressure. B. cereus grew at comparable charges to10(8) CFU/eye by 12 h, whatever the mouse pressure.
Retinal perform was preserved to a higher diploma in contaminated TLR2(-/-) eyes in comparison with that of contaminated wild kind eyes, however contaminated eyes of each mouse strains misplaced vital perform. Retinal structure was preserved in contaminated TLR2(-/-) eyes, with restricted retinal and vitreal mobile infiltration in comparison with that of contaminated wild kind eyes.
Ocular myeloperoxidase actions corroborated these outcomes. In normal, TNFα, IFNγ, IL6, and KC have been detected in higher concentrations in contaminated wild kind eyes than in contaminated TLR2(-/-) eyes. The absence of TLR2 resulted in decreased intraocular proinflammatory cytokine/chemokine ranges and altered recruitment of inflammatory cells into the attention, leading to much less intraocular irritation and preservation of retinal structure, and a barely higher diploma of retinal perform. These outcomes show TLR2 is a crucial element of the preliminary ocular response to B. cereus endophthalmitis.
Increased expression of <em>TLR</em>-<em>2</em>, COX-<em>2</em>, and SOD-<em>2</em> genes within the peripheral blood leukocytes of opisthorchiasis sufferers induced by Opisthorchis viverrini antigen.
Re-infection with liver fluke, Opisthorchis viverrini, will increase proinflammatory molecules concerned in inflammation-mediated illness and carcinogenesis in an animal mannequin. To make clear whether or not these genes reply to parasite antigen in peripheral blood leukocytes (PBL) of opisthorchiasis sufferers, we examined the transcriptional degree of oxidant-generating (toll-like receptor 2 (TLR-2), nuclear factor-kappa B (NF-KB), and cyclooxygenase 2 (COX-2)), anti-oxidant-generating (manganese superoxide dismutase 2 (SOD-2) and catalase (CAT)), proinflammatory cytokine (interleukin (IL)-1β), and anti inflammatory cytokine (IL-10), in PBL uncovered to parasite antigen in O. viverrini-infected sufferers in contrast with wholesome people in an in vitro experiment.
After O. viverrini antigen-treated PBL, quantitative RT-PCR evaluation revealed that elevated expression of cytokines and oxidant-generating genes in PBL was comparable between O. viverrini-infected and wholesome teams. Interestingly, in contrast with wholesome topics, improve of TLR-2, COX-2, and SOD-2 and decreased CAT mRNA expression ranges have been noticed in O. viverrini-infected group.
The outcomes point out that O. viverrini antigen induces upregulation of TLR-2, COX-2, and SOD-2 and downregulation of CAT genes in opisthorchiasis sufferers, suggesting that imbalance of oxidant/anti-oxidant transcripts throughout re-infection could also be concerned within the inflammatory-driven carcinogenesis. These molecules could also be used because the chemopreventive goal for intervention of opisthorchiasis sufferers in an endemic space.
Propolis immunomodulatory exercise on <em>TLR</em>-<em>2</em> and <em>TLR</em>-Four expression by chronically confused mice.
Our group has been investigating the immunomodulatory exercise of propolis in confused mice. In this work, we want to report the motion of propolis in chronically confused mice, assessing the Toll-like receptor (TLR-2 and TLR-4) expression by spleen cells and corticosterone ranges as a stress indicator. Male C57BL/6 mice have been divided into 4 teams: G1 was thought of the management; G2 was handled with propolis (200 mg kg(-1)); G3 was submitted to restraint stress for 14 days; and G4 was handled with propolis and instantly submitted to emphasize.
After sacrifice, spleens have been eliminated and TLR-2 and TLR-Four gene expression was analysed. TLR-2 and TLR-Four expression was elevated in propolis-treated mice, and propolis administration to confused mice prevented the inhibition of TLR-2 and TLR-Four expression. No variations have been seen within the corticosterone ranges among the many teams.
 TLR3 Peptide |
|||
| MBS152214-5x005mg | MyBiosource | 5x0.05mg | EUR 770 |
TLR3 Peptide |
|||
| MBS152737-005mg | MyBiosource | 0.05mg | EUR 175 |
TLR3 Peptide |
|||
| MBS152737-5x005mg | MyBiosource | 5x0.05mg | EUR 770 |
TLR3 Peptide |
|||
| MBS544578-025mg | MyBiosource | 0.25mg | EUR 280 |
TLR3 Peptide |
|||
| MBS544578-5x025mg | MyBiosource | 5x0.25mg | EUR 1110 |
 TLR3 Blocking Peptide |
|||
| 3445RBP-50 | Biovision | each | EUR 183.6 |
TLR3 Blocking Peptide |
|||
| DF6415-BP | Affbiotech | 1mg | EUR 234 |
TLR3 Blocking Peptide |
|||
| MBS9625788-1mg | MyBiosource | 1mg | EUR 380 |
TLR3 Blocking Peptide |
|||
| MBS9625788-5x1mg | MyBiosource | 5x1mg | EUR 1650 |
TLR3 Blocking Peptide |
|||
| MBS9617966-1mg | MyBiosource | 1mg | EUR 380 |
TLR3 Blocking Peptide |
|||
| MBS9617966-5x1mg | MyBiosource | 5x1mg | EUR 1650 |
 / Peptide 401) Mast Cell-Degranulating Peptide (MCD Peptide) / Peptide 401 |
|||
| 004-04 | PHOENIX PEPTIDE | 100 μg | EUR 140.4 |
 Peptide T |
|||
| 057-01 | PHOENIX PEPTIDE | 5 mg | EUR 140.4 |
 FGL Peptide |
|||
| 073-36 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
 APK peptide |
|||
| 076-81 | PHOENIX PEPTIDE | 200 μg | EUR 199.8 |
 NEF peptide |
|||
| 076-83 | PHOENIX PEPTIDE | 500 μg | EUR 140.4 |
 SHA peptide |
|||
| 076-84 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
 YSY peptide |
|||
| 076-86 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
 PSTAIR Peptide |
|||
| 070-61 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
) Peptide E / 3200-Dalton Adrenal Enkephalin-Containing Peptide (Bovine) |
|||
| 024-57 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
 PGMtide Peptide |
|||
| 040-69 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
 Adjuvant Peptide |
|||
| 070-05 | PHOENIX PEPTIDE | 500 μg | EUR 36.72 |
 Peptide-epsilon |
|||
| 058-22 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
 Delicious Peptide |
|||
| 070-21 | PHOENIX PEPTIDE | 5 mg | EUR 160.92 |
) proSex peptide (20-55) |
|||
| 040-30 | PHOENIX PEPTIDE | 100 μg | EUR 355.32 |
) proSex peptide (28-55) |
|||
| 040-31 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
) proSex peptide (40-55) |
|||
| 040-32 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
 Peptide F-9 |
|||
| 038-06 | PHOENIX PEPTIDE | 200 μg | EUR 58.32 |
 amide / prepro-Bombinin-Like Peptide (107-133) amide) Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide |
|||
| 007-60 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
) Sturgeon Peptide (137-158) |
|||
| 021-94 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
) Peptide Lv (Rat) |
|||
| 008-73 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
 NGR Peptide 1 |
|||
| 025-74 | PHOENIX PEPTIDE | 200 μg | EUR 184.68 |
 Anorexigenic Peptide |
|||
| 070-10 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
 (1-13) / GnRH Precursor Peptide (14-26) (Human)) GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human) |
|||
| 029-03 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
 (1-24) / GnRH Precursor Peptide (14-37) (Human)) GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human) |
|||
| 029-04 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
 (1-53) / GnRH Precursor Peptide (14-66) (Human)) GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human) |
|||
| 029-05 | PHOENIX PEPTIDE | 20 μg | EUR 267.84 |
 (25-53) / GnRH Precursor Peptide (38-66) (Human)) GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human) |
|||
| 029-06 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
 Bid BH3 peptide |
|||
| 025-87 | PHOENIX PEPTIDE | 1 mg | EUR 170.64 |
 AF-16 Peptide |
|||
| 033-44 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
) Peptide Lv (Human) |
|||
| 008-71 | PHOENIX PEPTIDE | 100 μg | EUR 405 |
) Peptide Lv (Mouse) |
|||
| 008-72 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
 (1-13) / Gn-RH Precursor Peptide (14-26) (Rat)) GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat) |
|||
| 029-08 | PHOENIX PEPTIDE | 200 μg | EUR 64.8 |
 ExE peptide M3mP6 |
|||
| 064-33 | PHOENIX PEPTIDE | 200 μg | EUR 244.08 |
) Peptide B (Bovine) |
|||
| 024-56 | PHOENIX PEPTIDE | 200 μg | EUR 81 |
) Peptide F (Bovine) |
|||
| 024-58 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
 (Bovine)) PLP Peptide (103-116) (Bovine) |
|||
| 070-14 | PHOENIX PEPTIDE | 5 mg | EUR 140.4 |
 FMRF-Like Peptide |
|||
| 047-32 | PHOENIX PEPTIDE | 1 mg | EUR 27 |
) Joining Peptide (Rat) |
|||
| 047-91 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
 (Frog)) Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog) |
|||
| 048-80 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
 (Frog)) Growth Hormone-Releasing Peptide-Related Peptide-2 (fGRP-RP-2) (Frog) |
|||
| 048-81 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
 (Frog)) Growth Hormone-Releasing Peptide-Related Peptide-3 (fGRP-RP-3) (Frog) |
|||
| 048-82 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
) Peptide T (4-8) |
|||
| 057-04 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
) Peptide T (5-8) |
|||
| 057-05 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
) Vasonatrin Peptide (VNP) |
|||
| 005-47 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
 Opioid Peptide Library |
|||
| L-002 | PHOENIX PEPTIDE | 58 peptides | EUR 2691.36 |
 / Porcine Intestinal Peptide (Porcine)) Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) |
|||
| 064-01 | PHOENIX PEPTIDE | 200 μg | EUR 108 |
 PGMtide Control Peptide |
|||
| 040-70 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
 Growth Blocking Peptide |
|||
| 046-92 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
 Neuron Specific Peptide |
|||
| 047-55 | PHOENIX PEPTIDE | 200 μg | EUR 140.4 |
 Heparin Binding Peptide |
|||
| 025-47 | PHOENIX PEPTIDE | 500 μg | EUR 102.6 |
 Gastrin Related Peptide |
|||
| 027-09 | PHOENIX PEPTIDE | 5 mg | EUR 73.44 |
 Obesity Peptide Library |
|||
| L-003 | PHOENIX PEPTIDE | 160 peptides | EUR 7267.32 |
 [D-Ala1]-Peptide T |
|||
| 057-02 | PHOENIX PEPTIDE | 5 mg | EUR 282.96 |
 (Human)) Peptide YY (PYY) (Human) |
|||
| 059-01 | PHOENIX PEPTIDE | 200 μg | EUR 119.88 |
 Eledoisin Related Peptide |
|||
| 046-04 | PHOENIX PEPTIDE | 5 mg | EUR 58.32 |
 - EIA Kit) proSex peptide (28-55) - EIA Kit |
|||
| EK-040-31 | PHOENIX PEPTIDE | 96 wells | EUR 603.72 |
) Peptide F 1 (Lobster) |
|||
| 047-62 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
 Morphine Tolerance Peptide |
|||
| 050-13 | PHOENIX PEPTIDE | 1 mg | EUR 102.6 |
 Phosphate Acceptor Peptide |
|||
| 058-24 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
 / Peptide Histidine Isoleucine (PHI) (Human)) Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) |
|||
| 064-07 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
 (1-26) (Aplysia brasiliana)) Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia brasiliana) |
|||
| 047-39 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
 (29-40) (Aplysia brasiliana)) Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia brasiliana) |
|||
| 047-40 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
 (1-26) (Aplysia californica)) Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia californica) |
|||
| 047-42 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
 (29-40) (Aplysia californica)) Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia californica) |
|||
| 047-43 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
 FGL Peptide - FAM Labeled |
|||
| FG-073-36A | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
 FGL Peptide - Cy3 Labeled |
|||
| FC3-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 672.84 |
 FGL Peptide - Cy5 Labeled |
|||
| FC5-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 756 |
 (Aplysia)) Pedal Peptide (Pep) (Aplysia) |
|||
| 047-61 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
 ExE peptide M3mP6 mutant |
|||
| 064-35 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
ExE peptide M3mP6 mutant |
|||
| 064-37 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
 FGL Peptide - FITC Labeled |
|||
| FG-073-36B | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
 AF-16 Peptide - Antibody |
|||
| H-033-44 | PHOENIX PEPTIDE | 100 μl | EUR 336.96 |
 Schizophrenia Related Peptide |
|||
| 047-79 | PHOENIX PEPTIDE | 5 mg | EUR 44.28 |
 Peptide) Insulin B (22-25) Peptide |
|||
| 035-08 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
) Eosinophilotactic Peptide (AGSE) |
|||
| 070-28 | PHOENIX PEPTIDE | 5 mg | EUR 27 |
) Eosinophilotactic Peptide (VGSE) |
|||
| 070-29 | PHOENIX PEPTIDE | 5 mg | EUR 27 |
) Cell Penetrating ARF Peptide (26-44) |
|||
| 068-56 | PHOENIX PEPTIDE | 500 μg | EUR 640.44 |
 FGL Peptide - Biotin Labeled |
|||
| B-073-36 | PHOENIX PEPTIDE | 20 μg | EUR 405 |
 - Antibody) Peptide F (Bovine) - Antibody |
|||
| H-024-58 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
 Library) Brain Peptide (Bees) Library |
|||
| L-007 | PHOENIX PEPTIDE | 51 peptides | EUR 6456.24 |
 / Porcine Intestinal Peptide (Porcine) - RIA Kit) Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - RIA Kit |
|||
| RK-064-01 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
 Gastrointestinal Peptide Library |
|||
| L-006 | PHOENIX PEPTIDE | 200 peptides | EUR 7267.32 |
 Peptide R / CXCR4 Antagonist |
|||
| 030-25 | PHOENIX PEPTIDE | 200 μg | EUR 203.04 |
 PGMtide Peptide - FAM Labeled |
|||
| FG-040-69A | PHOENIX PEPTIDE | 5 nmol | EUR 537.84 |
 PGMtide Peptide - Cy3 Labeled |
|||
| FC3-040-69 | PHOENIX PEPTIDE | 1 nmol | EUR 925.56 |
 [D-Arg14, D-Arg15]-MGF Peptide amide / C-terminal peptide of IGF-1 Ec amide |
|||
| 033-34 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
 / Peptide Histidine Isoleucine (PHI) (Human) - Antibody) Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Antibody |
|||
| H-064-07 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
 [D-Ala1]-Peptide T amide |
|||
| 057-03 | PHOENIX PEPTIDE | 500 μg | EUR 140.4 |
 - RIA Kit) Peptide F (Bovine) - RIA Kit |
|||
| RK-024-58 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
 Calmodulin Binding Peptide 1 |
|||
| 070-17 | PHOENIX PEPTIDE | 20 μg | EUR 214.92 |
) Catch-Relaxing Peptide (CARP) |
|||
| 047-20 | PHOENIX PEPTIDE | 1 mg | EUR 199.8 |
 FGL Peptide - Rhodamine Labeled |
|||
| FR-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 537.84 |
) Peptide-Depleted Plasma (Rat) |
|||
| MB-099-02 | PHOENIX PEPTIDE | 2 ml | EUR 119.88 |
 / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit) Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit |
|||
| RK-064-07 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
 Glycogenolysis-Inhibiting Peptide |
|||
| 023-63 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
 Anti-Inflammatory Peptide 1 |
|||
| 004-01 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
 Anti-Inflammatory Peptide 2 |
|||
| 004-02 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
 Anti-Inflammatory Peptide 3 |
|||
| 004-03 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
 Urokinase-Derived Peptide A6 |
|||
| 025-12 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
 PGMtide Peptide - Biotin Labeled |
|||
| B-040-69 | PHOENIX PEPTIDE | 20 μg | EUR 537.84 |
 Peptide 34 / GPR-54 Agonist |
|||
| 048-94 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
 FGL Peptide - I-125 Labeled |
|||
| T-073-36 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
) Peptide-Depleted Plasma (Human) |
|||
| MB-099-01 | PHOENIX PEPTIDE | 2 ml | EUR 119.88 |
 / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled) Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled |
|||
| FG-064-07A | PHOENIX PEPTIDE | 1 nmol | EUR 336.96 |
 / Porcine Intestinal Peptide (Porcine) - I-125 Labeled) Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - I-125 Labeled |
|||
| T-064-01 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
 F3 Peptide / HMGN2 Fragment 3 |
|||
| 004-12 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
 Antimicrobial Trp-rich peptide |
|||
| 004-05 | PHOENIX PEPTIDE | 100 μg | EUR 140.4 |
 Myosin Kinase Inhibiting Peptide |
|||
| 058-20 | PHOENIX PEPTIDE | 500 μg | EUR 50.76 |
) Fibronectin CS1 Peptide (EILDVPST) |
|||
| 025-20 | PHOENIX PEPTIDE | 500 μg | EUR 86.4 |
 (3-36) (Human)) Peptide YY (PYY) (3-36) (Human) |
|||
| 059-02 | PHOENIX PEPTIDE | 200 μg | EUR 102.6 |
 (Human) - Antibody) Peptide YY (PYY) (Human) - Antibody |
|||
| H-059-01 | PHOENIX PEPTIDE | 100 μl | EUR 469.8 |
 PGMtide Peptide - Rhodamine Labeled |
|||
| FR-040-69 | PHOENIX PEPTIDE | 5 nmol | EUR 604.8 |
 Anti-Angiogenic Peptide Library |
|||
| L-008A | PHOENIX PEPTIDE | 88 peptides | EUR 6067.44 |
 / Porcine Intestinal Peptide (Porcine) - Purified IgG Antibody) Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - Purified IgG Antibody |
|||
| G-064-01 | PHOENIX PEPTIDE | 400 μg | EUR 438.48 |
) Peptide A / p60v-src (137-157) |
|||
| 058-21 | PHOENIX PEPTIDE | 500 μg | EUR 135 |
Propolis exerted an immunomodulatory motion in chronically confused mice, upregulating TLR-2 and TLR-Four mRNA expression, contributing to the popularity of microorganisms and favouring the preliminary steps of the immune response throughout stress.
